ClinicalTrials.gg
RecruitingNCT07870330Updated Nov 5, 2026

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children

A Phase 1 interventional study of mRNA-1010 and Fluarix Trivalent in Seasonal Influenza, sponsored by ModernaTX, Inc.. Recruiting at 6 sites in United States. Open to participants aged 9 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
9 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Planned enrollment
12th of 12
96 · median 471
Started
2026
with 1 other
Phase 1
3 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 12th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 11th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 9 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to \<18 years of age).

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • Flu
  • Influenza
  • Vaccine
  • mRNA vaccine
  • mRNA-1010
  • Moderna
04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 9 to \<18 years of age inclusive, at the time of signing the /assent.
  • In the Investigator's opinion, the participants/participant's parent(s)/legally authorized representative (LAR(s)) demonstrate adequate understanding of the study requirements and are willing and physically able to comply with protocol mandated follow-up, including all procedures.
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.

Exclusion criteria

Exclusion Criteria:

  • History of anaphylaxis or severe reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic; influenza vaccine; or components of influenza vaccine, including egg protein.
  • Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1. Participants who are acutely ill or febrile may be scheduled for a separate dosing visit within the window specified for Screening.
  • History of a diagnosis or condition not specifically listed as exclusionary that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures.
  • Any prior systemic , immunomodulators (for example, methotrexate, cyclosporine), or long-acting biological therapies that may affect immune responses (for example, dupilumab, omalizumab). Short courses (\<7 days) of oral are allowed if completed at least 3 months prior to Day 1. Inhaled, nasal, topical steroids, and subcutaneous injected allergy immunotherapy (allergy shots) are allowed.
  • Received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive them during the study.
  • Received any nonstudy vaccine authorized or approved by local health agency within 14 days (28 days for and mRNA vaccines) prior to Day 1 (inclusive) or plans to receive any nonstudy vaccine within 28 days post study vaccine administration.
  • Donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study vaccine administration.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    mRNA-1010 Low Dose

    Participants will receive a single low dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    mRNA-1010 Full Dose

    Participants will receive a single full dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Fluarix Trivalent

    Participants will receive a single dose of Fluarix Trivalent by IM injection on Day 1.

    Biological: Fluarix Trivalent

Interventions

  • BiologicalmRNA-1010

    Suspension for injection

    Also known as: Seasonal influenza vaccine

  • BiologicalFluarix Trivalent

    Suspension for injection

    Also known as: A standard dose licensed inactivated seasonal influenza trivalent flu vaccine

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

    Time frame: Up to Day 7 (7 days after vaccination)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 28 (28 days after vaccination)

  3. Number of Participants with AEs Leading to Discontinuation, Serious Adverse Events (SAEs), or Adverse Events of Special Interest (AESI)

    Time frame: Day 1 through Day 365

  4. Number of Participants with Medically Attended AEs (MAAEs)

    Time frame: Day 1 through Day 181

  5. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay

    Time frame: Day 29

  6. Percentage of Participants Reaching Seroconversion, as Measured by HAI Assay

    Seroconversion is defined as either a pre-vaccination HAI titer \<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer.

    Time frame: Day 29

  7. Percentage of Participants With HAI Titer ≥ 1:40 at Day 29

    Time frame: Day 29

  8. Geometric Mean Fold Rise (GMFR) of Anti-HA antibodies, as Measured by HAI Assays

    Time frame: Day 29

07

Study locations

6 of 6 sites recruiting
  • Paradigm Clinical Research Centers, LLC
    Modesto, California 95355, United States
    Recruiting
  • Paradigm Clinical Research Centers, LLC
    Aurora, Colorado 80012, United States
    Recruiting
  • Clinical Research Institute, Inc
    Minneapolis, Minnesota 55402, United States
    Recruiting
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
    Recruiting
  • West Houston Clinical Research Service
    Houston, Texas 77055, United States
    Recruiting
  • Clinical Research Partners, LLC.
    Richmond, Virginia 23226, United States
    Recruiting
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 14 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartActual
Oct 7, 2026
Primary completionEst.
Dec 7, 2027
CompletionEst.
Dec 7, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Paradigm Clinical Research Centers, LLC · Modesto, United Statesno status→Recruiting
  • Paradigm Clinical Research Centers, LLC · Aurora, United Statesno status→Recruiting
  • Clinical Research Institute, Inc · Minneapolis, United Statesno status→Recruiting
  • Senders Pediatrics · South Euclid, United Statesno status→Recruiting
  • West Houston Clinical Research Service · Houston, United Statesno status→Recruiting
  • Clinical Research Partners, LLC. · Richmond, United Statesno status→Recruiting
across 2 updates, Oct 28, 2026 – Nov 5, 2026
Registered
First appeared on the registry
Oct 13, 2026
Show all 3 updates
  1. Nov 5, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Paradigm Clinical Research Centers, LLC · Aurora, United StatesNot yet recruiting→Recruiting
    • West Houston Clinical Research Service · Houston, United StatesNot yet recruiting→Recruiting
    • Clinical Research Partners, LLC. · Richmond, United StatesNot yet recruiting→Recruiting
    + 1 other change: verification date
  2. Oct 28, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (3 now recruiting, 3 now not yet recruiting)
    Show 6 sites
    • Paradigm Clinical Research Centers, LLC · Modesto, United Statesno status→Recruiting
    • Paradigm Clinical Research Centers, LLC · Aurora, United Statesno status→Not yet recruiting
    • Clinical Research Institute, Inc · Minneapolis, United Statesno status→Recruiting
    • Senders Pediatrics · South Euclid, United Statesno status→Recruiting
    • West Houston Clinical Research Service · Houston, United Statesno status→Not yet recruiting
    • Clinical Research Partners, LLC. · Richmond, United Statesno status→Not yet recruiting
    + 1 other change: date precision
  3. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07870330
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 7, 2026
Primary completion
Dec 7, 2027 (estimated)
Completion
Dec 7, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Moderna WeCare Team
Contact
WeCareClinicalTrials@modernatx.com
+1-866-663-3762

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion